Announced
Completed
Financials
Tags
Majority
biotechnology company
Biotechnology
Cross Border
Private
therapeutics
Acquisition
Friendly
Single Bidder
United Kingdom
Private Equity
Completed
Synopsis
Gilead Sciences, an American biopharmaceutical company, completed the acquisition of MiroBio, a biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, from Monograph, a fund manager, for $405m. “We are excited to be joining Gilead. MiroBio has a deep understanding of checkpoint receptor signaling and a proprietary approach to select and generate superior agonist antibodies. Combining this with Gilead’s drug development and therapeutic area expertise will allow us to fully explore the potential of checkpoint agonist antibodies for patients with autoimmune disease," Eliot Charles, MiroBio Chairman.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.